The Bevacizumab Market was valued at $6.78 billion and is projected to reach a market size of $8.91 billion by the end of 2030. Over the forecast period of 2025-2030, the market is projected to grow at a CAGR of 5.6%.
The Bevacizumab market is witnessing significant growth due to the growing cancer prevalence and development of biosimilars. The North American market contributes a major market share due to well-developed medical infrastructure and high cancer incidence rates. In 2024, the US region alone registered about 1.9 million new cancer diagnoses and 693,000 deaths related to cancer. Europe also has a high market share, led by regulatory approvals and biosimilar uptake, while the Asia-Pacific region is expected to experience strong growth due to growing healthcare spending and an expanding patient base. The market's growth is generally fueled by the need for affordable cancer treatments and continued product development innovations.
Key Market Insights:
Bevacizumab Market Key Drivers:
Rising Cancer Incidence Driving Demand for Bevacizumab Treatments
the creation of more efficient and targeted cancer drugs, improving the effectiveness of drugs such as Bevacizumab. Such advances are factors in the growth of the drug’s adoption and market.
Bevacizumab Market Restraints and Challenges:
The Bevacizumab market is beset by several key challenges and limitations that affect its growth trend. One such problem is the recent supply chain disruption; for example, Pine Pharmaceuticals, which is a primary supplier of repackaged Avastin (Bevacizumab), halted production in October 2024, which caused retina specialists to struggle to access the drug and potentially create delays in treatments for patients suffering from diseases such as age-related macular degeneration. In addition, the expensive price of Bevacizumab creates a hurdle towards universal usage, especially in developing countries. The cost of a year's treatment can be over $100,000, placing economic burdens on patients and health systems. Also, though biosimilars' introduction helps in cutting down expenses and improving access, their launch into the market is generally slowed by regulatory obstacles, mainly with respect to production processes and facility regulation. These delays can prevent timely access to cheaper treatment alternatives. Finally, safety issues related to Bevacizumab, including hypertension, bleeding, and thrombotic events, require careful monitoring. These side effects can restrict its use in some patient groups, thus limiting market growth.
Bevacizumab Market Opportunities:
The Subscription and Billing Management industry is expected to witness considerable growth, spurred by several emerging opportunities. The growth in the use of subscription business models in numerous industries requires sophisticated billing solutions for handling intricate pricing schemes and revenue recognition. With companies shifting from legacy sales to recurring revenues, the need for advanced subscription and billing management systems grows. The emergence of digital transformation programs further fuels this demand. Organizations are coming to rely on cloud-based offerings due to their scalability and adaptability, so they can handle subscription-based offerings efficiently. Further, the heightened focus on retaining customers and giving them a tailored experience opens opportunities for subscription and billing management platforms to increase satisfaction levels and churn rates. Businesses can encourage loyalty and keep competition at bay by offering customized price plans, offers, and promotions.
BEVACIZUMAB MARKET REPORT COVERAGE:
REPORT METRIC |
DETAILS |
Market Size Available |
2024 - 2030 |
Base Year |
2024 |
Forecast Period |
2025 - 2030 |
CAGR |
5.6% |
Segments Covered |
By Product Type, application, end user, , Distribution Channel and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
Key Companies Profiled |
Amgen Inc., Pfizer Inc., Mylan N.V., Samsung Bioepis, and Celltrion Healthcare Co., Ltd. |
Bevacizumab Market Segmentation:
While there is a long history of branded products leading the market, biosimilars are gaining ground. In America, biosimilars attained a patient share of more than 60% by 2024, and it is estimated that they will hold a share of the bevacizumab market equal to about 75% by the year 2030. This can be attributed to the cost benefits associated with biosimilars and their growing popularity in clinical practice
Of these, the oncology segment leads, mainly because of Bevacizumab's success in treating cancers like colorectal, lung, breast, and renal cell carcinoma. Its action of blocking angiogenesis, which is critical for tumor growth, has cemented its position in oncology treatment regimens. The increasing incidence of cancer worldwide further drives demand in this segment. On the other hand, the ophthalmology sector, for which Bevacizumab is being used off-label to cure diseases such as age-related macular degeneration and diabetic retinopathy, is growing at a phenomenal rate. This growth is related to an aging population and growing cases of diabetes, resulting in more cases of retinal illnesses. Thus, while oncology is the biggest market usage, the ophthalmology sector is the fastest growing one in the Bevacizumab market.
Hospital pharmacies lead the distribution channels in the Bevacizumab market today due to the specialized nature of cancer care requiring administration within hospital environments that have the necessary medical infrastructure. Yet, online pharmacies are proving to be the fastest-growing channel, facilitated by the rising use of digital healthcare solutions and the convenience of home delivery options. The growth of online e-commerce sites and improvements in logistics have enabled patients to access their drugs more conveniently online, fueling the fast growth of this channel.
Hospitals are the leading end-users in the Bevacizumab market, mainly because of the sophisticated nature of cancer therapy that requires specialized medical facilities and multidisciplinary medical teams provided within the hospital environment. This leadership is further supported by the intense need for Bevacizumab in oncology therapy, since the administration of advanced therapies is mainly provided within the primary centers operated by hospitals. Specialized oncology and ophthalmology clinics also play an important part, providing target therapies and patient-specific management. The convenience of and specialized service offered by the clinics account for their large portion in the market. Research institutions, as important as they are for driving clinical use and investigating new bevacizumab therapeutic uses, account for a smaller sector in terms of actual drug consumption. Their core focus is to perform clinical trials and translational research, thereby indirectly facilitating market expansion through widening the potential use of the drug.
The Bevacizumab market has characteristic regional trends with North America heading the market in light of established healthcare infrastructure and favorable regulatory environment. Europe stands next, given established biosimilar approval systems, followed by Asia-Pacific growing faster with growing instances of cancer cases and investments into healthcare. The Middle East & Africa and Latin America presently retain smaller shares in the market but offer promise to grow further in the future when healthcare infrastructures mature and more biosimilars are being adopted.
The COVID-19 pandemic influenced the Bevacizumab market in a variety of ways. On the one hand, the sales of Bevacizumab witnessed a significant rise, as shown by Amgen Inc.'s MVASI (Bevacizumab) U.S. sales, which jumped from USD 121 million in 2019 to USD 656 million in 2020. Outside the U.S., sales increased from USD 6 million in 2019 to USD 142 million in 2020. This rise can be linked to the efficacy of the drug in cancer therapy and its prospect in treating COVID-19-associated complications, including acute lung injury and acute respiratory distress syndrome. On the other hand, the pandemic resulted in a sharp decrease in intravitreal injections (IVI) of Bevacizumab for ophthalmic purposes. It was reported in a study conducted at Shaare Zedek Medical Center in Israel that there was a 44% drop in Bevacizumab IVIs from March 15 to April 14, 2020, from the corresponding period in 2019, mainly because patients were avoiding visits to healthcare centers during the fear of infection.
Recent Trends/Developments:
The Bevacizumab market has witnessed significant developments in the last few years, led notably by the introduction and regulatory approvals of biosimilars. In December 2023, the US FDA approved Bio-Thera Solutions' Avzivi (bevacizumab-tnjn), becoming the fifth bevacizumab biosimilar to be approved for the treatment of different types of cancers. The approval testifies to increased recognition and assimilation of biosimilars within oncology therapeutic regimens. Joint ventures have also defined the market scenario; for example, in July 2022, Prestige Biopharma Limited entered a collaboration with Intas Pharmaceuticals Limited to exclusively market Prestige's bevacizumab biosimilar in several countries to improve global access to affordable cancer treatments. In addition, market forecasts point to strong growth, with the global bevacizumab biosimilars market set to grow at a compound annual growth rate (CAGR) of 5.6%. This expansion is fueled by trends like the rising incidence of cancer and the need for affordable biologic drugs. Taken together, these trends reflect a dynamic market landscape, marked by regulatory innovation, strategic partnerships, and a commitment to increasing patient access to critical oncology drugs
Key Players in the Bevacizumab Market:
Chapter 1. Bevacizumab Market– Scope & Methodology
1.1. Market Segmentation
1.2. Scope, Assumptions & Limitations
1.3. Research Methodology
1.4. Primary Sources`
1.5. Secondary Sources
Chapter 2. Global Bevacizumab Market– Executive Summary
2.1. Market Size & Forecast – (2025 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.2.1. Demand Side
2.2.2. Supply Side
2.3. Attractive Investment Propositions
2.4. COVID-19 Impact Analysis
Chapter 3. Bevacizumab Market– Competition Scenario
3.1. Market Share Analysis & Company Benchmarking
3.2. Competitive Strategy & Development Scenario
3.3. Competitive Pricing Analysis
3.4. Supplier-Distributor Analysis
Chapter 4. Global Bevacizumab Market- Entry Scenario
4.1. Regulatory Scenario
4.2. Case Studies – Key Start-ups
4.3. Customer Analysis
4.4. PESTLE Analysis
4.5. Porters Five Force Model
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Powers of Customers
4.5.3. Threat of New Entrants
4.5.4. Rivalry among Existing Players
4.5.5. Threat of Substitutes
Chapter 5. Bevacizumab Market- Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. Global Bevacizumab Market– By Product Type
6.1 Introduction/Key Findings
6.2 Branded Products
6.3 Biosimilars
6.4 Y-O-Y Growth trend Analysis By Product Type
6.5 Absolute $ Opportunity Analysis By Product Type , 2025-2030
Chapter 7. Global Bevacizumab Market– By Application
7.1 Introduction/Key Findings
7.2 Oncology
7.3 Ophthalmology
7.4 Others
7.5 Y-O-Y Growth trend Analysis By Application
7.6 Absolute $ Opportunity Analysis By Application , 2025-2030
Chapter 8. Global Bevacizumab Market– By Distribution Channel
8.1 Introduction/Key Findings
8.2 Hospital Pharmacies
8.3 Retail Pharmacies and Drug Stores
8.4 Online Pharmacies Y-O-Y Growth trend Analysis Distribution Channel
8.5 Absolute $ Opportunity Analysis Distribution Channel , 2025-2030
Chapter 9. Global Bevacizumab Market– By End-User Industry
9.1 Introduction/Key Findings
9.2 Hospitals
9.3 Clinics
9.4 Research Institutes
9.5 Y-O-Y Growth trend Analysis End-User Industry
9.6 Absolute $ Opportunity Analysis End-User Industry , 2025-2030
Chapter 10. Bevacizumab Market, By Geography – Market Size, Forecast, Trends & Insights
10.1. North America
10.1.1. By Country
10.1.1.1. U.S.A.
10.1.1.2. Canada
10.1.1.3. Mexico
10.1.2. By Product Type
10.1.3. By Distribution Channel
10.1.4. By Application
10.1.5. End-User Industry
10.1.6. Countries & Segments - Market Attractiveness Analysis
10.2. Europe
10.2.1. By Country
10.2.1.1. U.K.
10.2.1.2. Germany
10.2.1.3. France
10.2.1.4. Italy
10.2.1.5. Spain
10.2.1.6. Rest of Europe
10.2.2. By Product Type
10.2.3. By Distribution Channel
10.2.4. By Application
10.2.5. End-User Industry
10.2.6. Countries & Segments - Market Attractiveness Analysis
10.3. Asia Pacific
10.3.1. By Country
10.3.1.2. China
10.3.1.2. Japan
10.3.1.3. South Korea
10.3.1.4. India
10.3.1.5. Australia & New Zealand
10.3.1.6. Rest of Asia-Pacific
10.3.2. By Product Type
10.3.3. By End-User Industry
10.3.4. By Application
10.3.5. Distribution Channel
10.3.6. Countries & Segments - Market Attractiveness Analysis
10.4. South America
10.4.1. By Country
10.4.1.1. Brazil
10.4.1.2. Argentina
10.4.1.3. Colombia
10.4.1.4. Chile
10.4.1.5. Rest of South America
10.4.2. By End-User Industry
10.4.3. By Application
10.4.4. By Product Type
10.4.5. Distribution Channel
10.4.6. Countries & Segments - Market Attractiveness Analysis
10.5. Middle East & Africa
10.5.1. By Country
10.5.1.4. United Arab Emirates (UAE)
10.5.1.2. Saudi Arabia
10.5.1.3. Qatar
10.5.1.4. Israel
10.5.1.5. South Africa
10.5.1.6. Nigeria
10.5.1.7. Kenya
10.5.1.10. Egypt
10.5.1.10. Rest of MEA
10.5.2. By Distribution Channel
10.5.3. By End-User Industry
10.5.4. By Application
10.5.5. Product Type
10.5.6. Countries & Segments - Market Attractiveness Analysis
Chapter 11. Global Bevacizumab Market– Company Profiles – (Overview, Service Product Type Portfolio, Financials, Strategies & Developments)
11.1 Genentech, Inc. (a member of the Roche Group)
11.2 Amgen Inc.
11.3 Pfizer Inc.
11.4 Mylan N.V.
11.5 Samsung Bioepis
11.6 Celltrion Healthcare Co., Ltd.
11.7 Prestige Biopharma
11.8 Fujifilm Kyowa Kirin Biologics
11.9 AryoGen Pharmed
11.10 Zydus Cadila
2500
4250
5250
6900
Frequently Asked Questions
The market is expected to grow from US $6.78 billion in 2025 to US $8.91 billion by 2030, at a CAGR of 5.6%.
Several companies are actively involved in the Bevacizumab biosimilars market, including Amgen Inc., Pfizer Inc., Mylan N.V., Samsung Bioepis, and Celltrion Healthcare Co., Ltd.
Common side effects of Bevacizumab include nosebleeds and high blood pressure. Serious and potentially fatal side effects can include gastrointestinal perforation, abnormal passage formation (fistula), wounds that don't heal, and severe bleeding.
The introduction of biosimilars has increased competition in the Bevacizumab market, leading to more treatment options and potentially lower costs for patients. This has also prompted healthcare providers and insurers to evaluate preferred products for oncology therapies.
Patients may have access to financial assistance programs offered by Genentech, the manufacturer of Avastin (Bevacizumab). These programs are designed to help patients afford their prescribed medication, regardless of their insurance status.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.